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During the 40th Annual Meeting of The Toxicology Forum, the current and potential future science,
regulations, and politics of agricultural biotechnology were presented and discussed. The meeting ses-
sion described herein focused on the technology of RNA interference (RNAi) in agriculture. The general
process by which RNAi works, currently registered RNAi-based plant traits, example RNAi-based traits in
development, potential use of double stranded RNA (dsRNA) as topically applied pesticide active in-
gredients, research related to the safety of RNAi, biological barriers to ingested dsRNA, recent regulatory
RNAi science reviews, and regulatory considerations related to the use of RNAi in agriculture were dis-
cussed. Participants generally agreed that the current regulatory framework is robust and appropriate for
evaluating the safety of RNAi employed in agricultural biotechnology and were also supportive of the use
of RNAi to develop improved crop traits. However, as with any emerging technology, the potential range
of future products, potential future regulatory frameworks, and public acceptance of the technology will
continue to evolve. As such, continuing dialogue was encouraged to promote education of consumers
and science-based regulations.
© 2015 Elsevier Inc. All rights reserved.1. Introduction (Sherman)
The mission of The Toxicology Forum is to encourage open
dialogue on human health and environmental issues that drive
public concerns, academic involvement, industry action and regu-
latory decision making. The dialogue at their meetings facilitates
conﬂict resolution, identiﬁes research gaps, drives researchstranded RNA; EFSA, Euro-
ministration; FIFRA, Federal
netically engineered; GMO,
Vs, microvesicles; NGO, non-
reaction; PIP, plant-incorpo-
ced silencing complex; RNAi,
RNA, small interfering RNA;
s Environmental Protection
culture-Agricultural Research
.H. Sherman).
versity of Pittsburgh Medical
tates.agendas, and promotes sound regulatory and policy decision
making (www.toxforum.org). This manuscript summarizes the
second half of a day-long session on Agricultural Biotechnology at
the 40th Annual Summer Meeting of The Toxicology Forum, which
focused on RNA interference (RNAi) and its current and potential
role in improving crop yields and nutritional quality. The ﬁrst half of
the day-long session focused on transgenic proteins in agricultural
biotechnology and is summarized in the preceding companion
manuscript (Sherman et al., 2015).
2. Introduction to the transformative technology of RNAi:
how RNAi is being used in agricultural biotechnology
(Munyikwa)
Many natural processes in eukaryotic organisms (plants, insects,
animals, and nematodes etc.) such as the regulation of gene
expression, suppression of invading viruses, and overall protection
of the genome have been shown to bemediated by small RNAs. This
occurs via a process now universally called RNAi (Fire et al., 1998;
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et al., 2006; Mallory and Vaucheret, 2006; Huvenne and Smagghe,
2010). The term RNAi was popularized by Fire and Mello following
their Nobel Prize winning work in Science or Medicine (2006)
which demonstrated the potent effects of double stranded RNA
(dsRNA) in Caenorhabditis elegans (Fire et al., 1998) and initiated
intense research to understand the mechanisms underlying RNAi
and its potential uses.
The basis of RNAi involves gene suppression at the transcription
level or post transcriptional level. Suppression of gene expression is
initiated by long dsRNAs that can emanate internally within or are
introduced from outside a cell. A generalized description of the
RNAi pathway is shown in Fig. 1. The long dsRNAs are cleaved by
endonucleases such as Dicer and the Dicer-like proteins, to produce
small interfering RNAs (siRNAs) which are double stranded RNAs
that are on average 21e27 base pairs in length. The siRNAs complex
with other proteins into an RNA Induced silencing complex (RISC)
which unwinds and separates the two strands allowing for the
speciﬁc base pairing between the small RNA and the targeted
mRNA. This leads to reduction in the copy number of the speciﬁc
mRNA by enzyme cleavage or lower protein concentration by
suppression of translation. Ultimately the corresponding protein
and its associated function are suppressed or eliminated within
that organism's cells (Hamilton and Baulcombe, 1999; Huntzinger
and Izaurralde, 2011). Other small RNAs that originate internally
within cells e.g. microRNA (miRNA) and trans-acting RNA (tasiRNA)
are also associated with the RNAi process in various organisms
(Vazquez et al., 2004; Wilson and Doudna, 2013).
The mechanism of RNAi shows some differences amongst eu-
karyotes, including: 1) the requirements for nearly perfect
complementarity for plant miRNAs as compared to animal miRNAs,Fig. 1. The RNAi Pathway. Diagram shows a generalized view of the RNAi pathway: (1) l
(tasiRNA)and micro RNA (miRNA) or b) externally from invading viruses, introduced dsRNA -
(siRNAs) that are on average 21e27 nt in size (2). The siRNAs duplexes generated complex wi
separates the two strands (4) The single strand siRNA-RISC complex targets a speciﬁc mRNA
This leads to the elimination of the speciﬁc mRNA by enzyme cleavage or suppression of tran
within that organism's cells. Recycling of the siRNA-RISC complex occurs (7) as well in plants
the small pool of siRNAs by RNA-Dependent RNA polymerase (8) that results in accumulatand 2) the existence of an intercellular spreading process in plants,
fungi and nematodes that has not yet been observed in insects or
vertebrates (Tomari and Zamore, 2005; Miller et al., 2012). The
intercellular spreading process involves ampliﬁcation of the initial
small pool of siRNAs by RNA-dependent RNA polymerase allowing
for accumulation and intercellular spread of the RNAi molecules,
via plasmodesmata and phloem in plants, or transmembrane type
proteins such as SID1 in worms (Mittelbrunn and Sanchez-Madrid,
2012; Hunter et al., 2006; Zhang and Ruvkun, 2012).
The ability to suppress mRNA expression has created numerous
new opportunities for the development of beneﬁcial RNAi appli-
cations for the pharmaceutical and agricultural areas (Baum et al.,
2007, Wu et al., 2014). For the latter, products that utilize the
RNAi mode of action have the potential to offer new and comple-
mentary insect, bacteria, fungal, viral, and weed control solutions
that have a degree of potency and selectivity beyond what has been
possible to date using conventional pesticides. These products can
be designed to precisely target speciﬁc mRNAs in a targeted species
for which they are developed while leaving other organisms un-
affected. The RNAi based products in development will be useful for
the control of resistant populations of plant pests due to their
unique mode of action. The agricultural industry is developing
these products due to their high potential for having improved
safety proﬁles and excellent speciﬁcity.
The delivery of products that utilize the RNAimode of action as a
biocontrol may occur as spray, drench, or granular applications.
Alternatively the RNAi mode of action can be initiated as a plant-
incorporated protectant (PIP) that is produced by a stably inte-
grated transgene. A growing number of in planta RNAi-based events
have been developed, reviewed, and received approval by inter-
national regulatory agencies, as shown in Table 1 below. Theseong dsRNAs - derived from a) internally from microRNA (miRNAs), trans-acting RNA
are cleaved by the endonuclease called Dicer to small double stranded interfering RNAs
th other proteins into an RNA Induced Silencing Complex (RISC) (3) which unwinds and
by speciﬁc Watson-Crick base pairing between the siRNA and the targeted mRNA (5)
slation (6) Ultimately the corresponding proteins and associated function is eliminated
, fungi and nematodes (but not vertebrates) where there is a process of ampliﬁcation of
ion and intercellular spread of the RNAi molecules. (Note: Would Prefer Color).
Table 1
In planta RNAi products that have been reviewed and approved by at least one international regulatory agency.
Older products New products/in development
TomatoeseFlavr Savr™ Tomato Delayed ripeningeMonsanto (1994)
SquasheVirus resistanceeMonsanto (1994)
CorneHigh lysineeRenessen (2005)
PlumeResistance to plum pox virus (PPV)eUSDA_ARS (2007)
SoybeaneModiﬁed Oil/Fatty acideDupont-Pioneer (2009)
 Papaya -Resistance to viral infection,
ring spot virus (PRSV)eUniversity of
Florida (2008)
 PapayaeResistance to papaya ring spot virus (PRSV)eCornell University and
University of Hawaii (1996).
 Soybean - Modiﬁed Oil/Fatty acideMonsanto (2011)
 SoybeaneHigh oleic acideDuPont Pioneer (1997)  Amylopectin potatoeBASF (2010)
 New Leaf Potato® YeMonsanto (1998)
 New Leaf Potato® PluseMonsanto (1998)
 Brazilian golden mosaic virus resistant beanseEmbrapae(2011)
 Reduced Lignin AlfalfaeMonsanto and Forage Genetics (2013)
 Innate PotatoeJ.R. Simplot (2014)
 Arctic™ “Golden Delicious” AppleeOkanagan Specialty Fruits (2015)
J.H. Sherman et al. / Regulatory Toxicology and Pharmacology 73 (2015) 671e680 673events encompass a wide variety of plant species from corn to
potato as well as a range of traits including virus resistance and oil
composition modiﬁcation (e.g., lower trans-fats) in soybean oil
(Frizzi and Huang, 2010).
Sprayable RNAi-based biocontrol products are still in develop-
ment. The United States Environmental Protection Agency (US EPA)
broadly anticipates that these products will fall under four cate-
gories, namely: 1) direct control agents; 2) resistance factor re-
pressors; 3) developmental disruptors; and 4) growth enhancers
(EPA, 2014). These RNA-based biocontrol products will likely be
used outdoors on ﬁeld crops and nurseries as well as indoors in
storage facilities, green houses, etc.
The development of crop protectants that leverage the naturally
occurring RNAi mode of action adds an additional agricultural
productivity tool that shares the vast history of exposure to, and
consumption of, small RNAs.
3. Are ingested small RNAs from plants signiﬁcantly absorbed
by humans? (Chan)
The past ﬁfteen years of scientiﬁc discovery has offered a wealth
of information about the biological activity of small non-coding
RNA molecules with RNAi activity in eukaryotic organisms. In
lower eukaryotes such as worms and insects (Issa et al., 2005;
Newmark et al., 2003; Timmons and Fire, 1998), ingestion of
exogenous RNAs allows for uptake and transfer of these molecules
systemically (Feinberg and Hunter, 2003; Fire et al.,1998). However,
ingestion of chemically synthesized RNA molecules designed for
RNAi in larger mammals has proven to be an exceedingly chal-
lenging route of administration for effective uptake and biological
activity, driven by the inherent instability of naked RNA oligonu-
cleotides, the harsh environment of the gastrointestinal tract, and
the lack of an identiﬁed speciﬁc molecular transporter in the gut for
access to the systemic circulation. Recently, the discovery of the
stability of extracellular microRNAs has re-invigorated a debate
about their hypothesized ability to survive the milieu of the
mammalian intestinal tract and transfer systemically to the host
organism (Fig. 2). Notably, extracellular miRNAs have been
discovered in a variety of body ﬂuids. Also referred to as secreted or
released miRNAs, these molecules are stable and can be packaged
within microvesicles (MVs) or partnered with lipoproteins and
RNA-binding molecules. They may be taken up by recipient cells
where, if present in great enough quantity, can suppress target gene
expression [as reviewed in (Creemers et al., 2012)].
In 2012, Zhang et al. reported that orally ingested, diet-derived
miRNAs frequently are taken up by the mammalian gut and into
systemic circulation (Zhang et al., 2012a). Their study focused on
MIR168a, amiRNA inplants and ricewhich they reported candirectly
regulate the expression of the low-density lipoprotein receptor
adapter protein 1 (LDLRAP1) in the liver and thus affect LDLcholesterol metabolism. Their team found high serum expression of
MIR168a, as well as other miRNAs (e.g., MIR156 and MIR166A), in
Chinese persons that maintained consistent ingestion of rice. Zhang
and colleagues also reported that mice ingesting a diet of rice (car-
rying endogenous MIR156a, MIR166a, and MIR168a) displayed
higher levels of thesemiRNAs in their serumand several solid organs
(Zhang et al., 2012a). Finally, mice fed with a diet of fresh rice for a
week displayed elevation of MIR168a in the liver and lower expres-
sion of LDLRAP1. A study by Wang and colleagues also detected a
broad spectrum of exogenous nucleic acids in human blood using
next-generation sequencing (Wanget al., 2012).However, in contrast
to Zhang and colleagues, they did not examine dietary intake and
MIR 168a was reported at an exceedingly low concentration.
Subsequent work has put the generalizability of these ﬁndings
into question (Fig. 3). The Chan laboratory studied three conserved
plant-derived miRNAs (MIR156A, MIR159A, and MIR169A) present
in fruits as well as one conserved mammalian miRNA (miR-21)
(Snow et al., 2013). These miRNAs were measured in human
plasma, in plasma of mice that had been fed a diet with high levels
of the three plant-derived miRNAs, and in plasma from mice
genetically null for miR-21 that had been fed a diet with high levels
of miR-21. All four exogenous miRNAs were detectable in some
cases, but at concentrations of less than one copy per cell, making
canonical miRNA activity unlikely. These concentrations differed
from the high levels of MIR168a reported by Zhang and colleagues
(approximately 850 copies per cell) (Zhang et al., 2012a).
The ﬁndings of the Chan laboratory were consistent with those
of Witwer et al. (Witwer et al., 2013) who reported on the plasma
miRNA content in pigtailed macaques following oral ingestion of a
plant miRNA-enriched shake. In serial plasma samples taken post-
ingestion, none of the plant-derived miRNAs chosen for study were
detectable except for MIR160 e but only at low levels and not
dependent upon shake ingestion. A third study published by
Dickinson and colleagues attempted to replicate the study by Zhang
et al. more directly (Dickinson et al., 2013). In that case, feeding of
rice-containing diets at two different incorporation levels allowed
for, at best, trace detection of plant-derived miRNAs in plasma that
did not correlate with levels of dietary consumption. Furthermore,
when examining LDLRAP1 and LDL cholesterol expression in these
mice, the authors concluded that fasting and an unbalanced
nutritional intake, not diet-derived miRNAs, drove the alterations
in LDL originally reported by Zhang et al. (Zhang et al., 2012a).
Notably, the detectability of trace levels of exogenous miRNAs in
mammalian plasma appears to be a reproducible ﬁnding across
independent reports. However, discrepancies have emerged
regarding the actual level of exogenous miRNA expression in
recipient organisms that can realistically be achieved through de-
livery from a typical mammalian diet alone. Speciﬁcally, in order to
deliver a biologically relevant amount of a given miRNA systemi-
cally throughout the human body as reported originally by Zhang
Fig. 2. Hypothesis of ingestion and uptake of diet-derived miRNAs in mammals. Given the stability of ex vivo miRNAs, it has been proposed that these molecules can survive the
mammalian gastrointestinal milieu after ingestion. Given the growing literature describing the uptake of extracellular miRNAs into recipient cells, a hypothesis has emerged that
these molecules can be transported through the gut into the systemic circulation and into recipient tissues in sufﬁcient quantities to exert biological functions in canonical or non-
canonical fashion. Images are adapted from Cottrill and Chan (2014), Gupta et al. (2010) with publisher permission.
Fig. 3. Current evidence regarding transfer of diet-derived miRNAs to recipient mammals. For: Exogenous miRNAs have been reported to have gene regulatory effects in one case
(Zhang et al., 2012a). Neutral: Exogenous RNAs have been detected in plasma and serum (Wang et al., 2012), Against: Experimental attempts to replicate oral uptake of miRNAs in
mammals have been unsuccessful, even in a direct replication of the experimental conditions under which MIR168a was ﬁrst reported to be taken up by rice-fed mice (Dickinson
et al., 2013; Snow et al., 2013; Witwer et al., 2013). In these studies, reported levels of exogenous miRNAs in mammalian serum and plasma have been inconsistent and often at low
concentrations not subject to dose-dependent ingestion. The extremely high sensitivity of quantitative PCR or next generation sequencing platforms can allow for detection of
contaminating miRNAs in human samples (Tosar et al., 2014; Zhang et al., 2012b), thus facilitating false-positive readings of exogenous miRNAs. Reprinted with permission.
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would need to consume the equivalent of approximately 1670 kg of
cantaloupe (Snow et al., 2013). This assumes 106 copies of a speciﬁc
plant-derived miRNA per mg of fruit, a minimum copy number of
100 copies per cell for canonical target gene repression, and 1013
cells in an average human body. Petrick and colleagues calculated a
similarly unattainable dietary consumption rate when recentlyreporting on the safety of genetically-modiﬁed crops (Petrick et al.,
2013). It remains conceivable that diets carrying concentrated
amounts of miRNA may facilitate increased delivery. However,
based on dosage levels alone, endogenous miRNAs present in
normal human diets are not numerous enough to attain high
enough levels in the bloodstream and recipient tissue to promote
canonical gene regulatory functions.
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sensitive technologies such as polymerase chain reaction (PCR) or
next-generation sequencing to detect single copies of diet-derived
miRNAs in recipient organisms. The occasional (and possibly non-
speciﬁc (Witwer et al., 2013)) ampliﬁcation of a plant sequence at
high cycle threshold (Ct) values (Snow et al., 2013; Witwer et al.,
2013) or fractional or single-digit high throughput sequencing
reads per million of a single plant miRNA (Wang et al., 2012) have
been noted in humanplasma. However, an all too commonproblem
of contaminating plant miRNAs has been reported by multiple
groups in recent analyses of library preparation for next-generation
sequencing (Zhang et al., 2012b) and particularly may have affected
Zhang and colleagues’ original work (Tosar et al., 2014). As such,
future studies interrogating the delivery of diet-derived miRNAs
should be conducted with extraordinary rigor to avoid such com-
mon pitfalls (Witwer and Hirschi, 2014).
So, where do we go from here? Theoretically, gastrointestinal
disease, genetic conditions, or ingested substances could change
gut permeability for exogenous miRNAs (and other molecules), and
potentially more efﬁcient uptake could increase the chances for
biological activity in the recipient subject. Alternatively, one could
envision that uptake may be improved by specialized packaging;
and if certain tissue niches within the body can act as repositories
for diet-derived miRNAs, these putative mechanisms could raise
exogenous miRNA concentrations to more biologically relevant
levels. Non-canonical actions of exogenous miRNAs (i.e., acting as
signaling ligands) are also conceivable which may require a lower
concentration for biological function. Additional studies are
ongoing worldwide to interrogate these possibilities. However,
recent dietary miRNA studies demonstrate deﬁnitively the absence
of generalized uptake of dietary miRNAs for canonical antisense
gene regulatory functions (Dickinson et al., 2013; Snow et al., 2013;
Witwer et al., 2013). They further suggest that previous ﬁndings of
uptake of exogenous miRNAs may have been affected by false-
positives due to contaminating signals when using exceptionally
sensitive techniques of miRNA measurements. Thus, while unan-
swered questions still remain in this ﬁeld, convincing and repro-
ducible evidence of uptake and delivery of diet-derived miRNAs at
biologically relevant levels has yet to emerge.
4. Mammalian biological barriers to absorption of ingested
dsRNA (Petrick)
In addition to the quantitative experimental evidence casting
doubt on the activity and uptake of ingested small RNAs as dis-
cussed above, there are extensive biological barriers to systemic
absorption and biodistribution of dsRNAs (Petrick et al., 2013). The
weight of the evidence indicates the limited potential for
physiologically-relevant absorption or biodistribution of diet-
derived dsRNAs (Table 2). There is a history of safe consumption
of dsRNA in our diets as evidenced by the presence of dsRNAs in all
plant and animal derived foods that we eat. This includes plant
dsRNAs with exact sequence matches to human genes/transcripts
(Ivashuta et al., 2009; Frizzi et al., 2014; Jensen et al., 2013).
Empirical evidence supporting the conclusion that diet-derived
dsRNA are of little health concern is also provided by pharmaceu-
tical research related to developing drugs based on RNAi technol-
ogies, where efforts to achieve oral efﬁcacy of candidate dsRNA
sequences in suppressing candidate target genes have largely been
unsuccessful. This is not surprising considering there is generally
very low (1%) bioavailability of oligonucleotide therapeutics
(reviewed in Petrick et al. (2013)). The conclusion of the general
safety of diet-derived dsRNA has also recently been articulated by
the Food Standards Australia New Zealand which stated: “There is
no scientiﬁc basis for suggesting that small dsRNAs present in someGM foods have different properties or pose a greater risk than those
already naturally abundant in conventional foods” (http://www.
foodstandards.gov.au/consumer/gmfood/Pages/Response-to-
Heinemann-et-al-on-the-regulation-of-GM-crops-and-foods-
developed-using-gene-silencing.aspx last accessed June 24, 2015).
The history of safe consumption of dsRNA and the absence of
efﬁcacious oral RNA therapeutics, on the market or under devel-
opment, is believed to largely result from multiple and redundant
biological barriers to absorption and/or biodistribution. Gastroin-
testinal, cellular, and systemic distribution barriers aremultifaceted
(Table 2). Additionally, relatively rapid systemic clearance and
degradation (e.g. within minutes) of circulating dsRNA (Thompson
et al., 2012; Christensen et al., 2013) further limits the potential for
ingested dsRNA to elicit an effect in the consuming organism. The
appropriateness and applicability of the existing safety assessment
framework for biotechnology-derived crops to those harnessing
RNAi was emphasized based on the weight of the evidence for
ingested RNA safety and the robustness of the existing case-by-case
comparative safety assessment approach.
To further investigate the potential for dsRNA to be absorbed
from the gut and distributed in biologically relevant concentrations,
a proof of concept 28-day oral toxicity study was performed using
dsRNAs targeting vacuolar ATPase, a sequence that is effective in
controlling corn rootworms (Baum et al., 2007) but which was
designed to have 100% sequence identity to the mouse ortholog
(mice were the test species). The study design was adapted from
OECD test guideline 407, but also included gene expression analysis
as a measure for potential suppression of the target gene (since
conference, data published in Petrick et al. (2015)). A 218 bp dsRNA
or a pool of four 21-mer vATPase siRNAs elicited no adverse effects
in either male or female mice after 28 days of exposure at the
highest doses of 64 mg/kg and 48 mg/kg, respectively. These
exposure levels are greater than 1,000,000-fold higher than antic-
ipated human exposures from biotech crops, based on one such
crop currently under development that utilizes RNA for insect
control, and thus represents very large margins of exposure. In
addition, no meaningful differences were noted in the level of
vATPase mRNA expression in the brain, liver, kidney, stomach, du-
odenum, ileum, and spleen. As such, even at concentrations vastly
greater than present in a normal diet, after daily oral ingestion for
28-days, dsRNAs with 100% homology to a mammalian transcript
within the test species were unable to elicit adverse effects in mice
or meaningfully impact the expression of the targeted gene.
The above results (since published as Petrick et al. (2015)) also
shed light on the potential utility of bioinformatics as a tool for risk
assessment of dsRNAs from RNAi-based crop traits; that is,
sequence matches are not predictive of hazard. Together with a
history of safe consumption of dsRNA in the diet and biological
barriers, the high-dose vATPase dietary study indicates that
sequence matches do not accurately predict a safety hazard in
mammals - even when the dsRNA shares an exact match with
endogenously expressed mRNA. As such, bioinformatics can iden-
tify putative matches, but does not appear to predict human health
hazards and, thus, does not appear to be informative as a risk
assessment tool.
5. Human health considerations for RNAi-Based pesticides:
reﬂections on the USEPA SAP and EFSA panel deliberations
(Witwer)
5.1. USEPA SAP
5.1.1. Background
Enforcement of the Federal Insecticide, Fungicide, and Roden-
ticide Act of 1947 (FIFRA) was transferred from the United States
Table 2
Safety of exogenous dsRNA in higher organisms.
Evidence Category Supporting evidence
History of Safe Consumption  Small RNAs and long dsRNAs with identity to human and animal transcripts are safely consumed in staple crops.
 RNAi is not new to agriculture and underlies many domesticated crop phenotypes, as well as approved biotech crop
traits
Efﬁcacy of oral RNAi pharmaceuticals  1% oral bioavailability of oligo therapeutics
 Direct injection, formulation, and stabilizing modiﬁcations needed for systemic activity
 siRNA drugs are extensively metabolized and are cleared by the kidneys within minutes after i.v. dosing
 Candidate RNA drugs have been safely administered at doses of up to 200 mg/kg i.v. in rats (Thompson et al., 2012)
Barriers to systemic distribution of
ingested RNA
 Saliva
 Stomach acid
 Pancreatic nucleases
 Intestinal epithelium and mucosa
 Vascular endothelium
 Blood/systemic nucleases
 Rapid renal ﬁltration (of any absorbed dsRNA)
Barriers to intracellular absorption and
distribution
 Plasma membrane
 Endosomal sequestration
 Lysosomal degradation
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Agency (USEPA) upon institution of the latter in 1970. In order to
gain the advice of experts on various topics coming before the EPA,
a FIFRA Scientiﬁc Advisory Panel (SAP) was later formed per the
Federal Advisory Committee Act of 1972. The SAP includes seven
permanent members who are nominated by federal entities such as
the National Institutes of Health and the National Science Foun-
dation. Holding approximately ﬁve to seven thematic meetings
each year, the SAP is augmented by ad hoc members of the Science
Review Board who are experts in areas relevant to the topic of each
panel. By law, each meeting must be public and provide members
of the public with the opportunity to present comments. Minutes
must be released within 90 days of the event. It should be noted
that the panelists are not required to form a consensus, and the
advice of the FIFRA-SAP may guide but does not constitute or
determine policy.5.1.2. RNAi SAP
A FIFRA-SAP on “RNAi technology as a pesticide: Problem
formulation for human health and ecological risk assessment” was
convened at US EPA headquarters on January 28, 2014 and included
three charge questions related to human health, as follows, and
four pertaining to environmental considerations.
Assigned to various charge questions were both ad hoc and
permanent SAP members. Of the nine members of the panel, seven
were assigned exclusively to either human health (Table 3) or
environment questions (not addressed here). As per guidelines,
charge question responses were prepared by assigned panelists
only and could not be shared with other panelists until the day of
the meeting. In contrast with the usual FIFRA-SAP two-day format,
this meeting was only one day in length, allowing less time for
panelists to discuss viewpoints and ﬁnalize responses accordingly.5.1.3. Human health considerations
Following a public comment session, primary respondents to
the charge questions entered their answers. The respondents to the
human health questions ﬁrst took up the topic of potential off-
target effects of RNAi effectors in mammals. Bioinformatics tools
and substantial genomic coverage allow rapid assessment of po-
tential binding sites of RNAi molecules in non-target organism
transcriptomes. However, these tools also return many false posi-
tives, and despite the presence of many predicted binding sites of
plant RNA in mammalian genomes, there is a history of safe
exposure to plants and their expressed dsRNAs in the diet.
The question of off-target effects is in any case irrelevant if thereis no functional exposure. Respondents emphasized the many bar-
riers to uptake and function of dietary RNA, from RNases that
degrade both single- and double-stranded RNA, to rapid clearance of
bloodstream RNA by the kidneys, and the lack of conﬁrmation of a
high-proﬁle report (Zhang et al., 2012a) that humans take up
regulation-relevant levels of microRNAs. Numerous attempts to
replicate these results, both published and unpublished, have found
no signiﬁcant uptake of dietary RNA (discussed above in Sections 2
and 3). These negative ﬁndings appeared to be consistent with the
understanding that many speciesdand all mammals, as far as is
knownddo not have the molecular machinery to take up environ-
mental RNA efﬁciently and incorporate it into RNA regulatory
pathways, with or without ampliﬁcation. Investigation of non-
dietary routes of exposure, such as contact or inhalation exposure,
might require further experimentation, asmight dietary exposure of
individuals with medical conditions predisposing to “leaky gut.”
However, independent calculations suggested that even 100% up-
take and distribution of dietary RNA into functional cellular RNAi
complexes could not result in per-cell copy numbers sufﬁcient to
regulate native messenger RNAs at physiologic levels of food intake
(Snow et al., 2013; Petrick et al., 2013; and discussed above). The
likelihood of “non-canonical” effects of ingested RNA, including
innate immune system stimulation, or saturation of the native RNAi
machinery, was also discussed. These effects, to the extent they
might occur, would appear to require even higher levels of exposure.
Differences in the perception of abundance of plant-
incorporated RNAi effector molecules were apparent amongst
panelists. One member referred to “unprecedented” levels of RNA
exposure and several were under the impression that the RNAi
plant incorporated protectants must be highly overexpressed in
planta. The question of abundance was thus posed to industry
representatives, who stated that the RNA in question was typically
found at very low abundance and was not among the most abun-
dant RNAs in the plant. Interestingly, in then-unpublished experi-
ments that were presented to the panel to establish the rapid
environmental degradation of RNAi protectants, RNA was almost
undetectable in planta, requiring the addition of exogenous RNA to
achieve reliable readings in the persistence assays. The effectiveness
of pesticidal RNAi mechanisms depends not on abundance of the
RNAi precursor, but on the ability of the ingesting organism to take
up dsRNA into cells and process it into short RNAi effectors.5.1.4. Conclusions
Overall, with the aforementioned potential exceptions of
specialized exposure routes or medical conditions, there was
Table 3
USEPA FIFRA SAP Human Health-Related Charge Questions and Assigned Panel Members. A ¼ Ad hoc SAP panel member; P¼Permanent SAP panel member.
Human health charge questions/Considerations Assigned panel members
1) Please discuss the nature and extent of uncertainty in the speciﬁcity of long sequences of
dsRNA targeted at pest species, if bioinformatic analysis shows no signiﬁcant similarity to
mammalian genes.
Brian Gregory (A), Brenda Oppert (A), Ken Witwer (A), Barry Delclos (P),
James McManaman (P)
2) Based on data indicating degradation of the majority of dsRNA in the digestive system,
please discuss the strengths and limitations in concluding there will not be signiﬁcant
adsorption of dsRNA with possible mammalian effects on oral exposure.
Brian Gregory (A), Brenda Oppert (A), Ken Witwer (A), Barry Delclos (P),
James McManaman (P)
3) To what extent does the speciﬁc structure of dsRNA, if it is super coiled or in a hairpin
structure, make it more likely to survive degradation in the gut and lead to possible
mammalian effects with oral exposure?
Brian Gregory (A), Brenda Oppert (A), Ken Witwer (A)
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effectors by humans is unlikely and inconsistent with the available
evidence (Table 2). This stood in contrast with the tenor of some of
the environmental responses, which called into question the
applicability of the current regulatory framework to evaluate po-
tential environmental effects of plant-incorporated RNAi.
5.2. EFSA workshop
The European Food Safety Authority (EFSA) held a two-day
workshop on the topic “Risk assessment considerations for RNAi-
based GM plants“ on June 4e5, 2014, in Brussels, Belgium. The
ﬁrst day of the meeting featured lectures on RNAi molecular
biology, applications, and risk assessment by academic scientists
such as Andrew Fire, co-discoverer of RNAi (Fire et al., 1998), and
both government and industry scientists. The second day of the
meeting was devoted to workshops on “Molecular characteriza-
tion,” “Food/feed risk assessment,” and “Environmental risk
assessment,” which included participants from activist organiza-
tions as well.
5.2.1. Hypothetical unknowns versus known toxicities
During the day of lectures, Andrew Fire acknowledged past
missteps by scientists in presuming the safety of the odd compound
or technology that was ultimately found to have harmful side ef-
fects, but also gave the analogy of the homeowner standing on her
roof, threatened by rising waters in a hurricane but refusing to
climb into a rescue helicopter [because it is perceived as unsafe].
RNAi technology, onemight conclude, could be an important tool in
achieving food security, one that could be much safer because of its
potential to be more speciﬁc and less toxic than conventional
chemical pesticides.
5.2.2. Dietary RNA-mediated regulation in humans?
Presenter Gunter Meister had recently published a method for
achieving knockdown in mammalian cells (Hannus et al., 2014).
This protocol used multiple siRNAs to minimize concentrations of
individual siRNA molecules and avoids off-target effects. The pro-
cess essentially mimics the normal processing of dsRNA in non-
mammalian organisms that are capable of importing dsRNA and
processing it into a pool of siRNAs, and suggests that the extremely
low levels of individual RNAi effectors (e.g., siRNAs) in ingested
plants are unlikely to have off-target effects in mammals due to the
impact of dilution with siRNA pools.
A questioner asked about survival and function of a plant miRNA
or plant miRNA-protein complex in a mammalian cell. It was
deemed unlikely that an uncomplexed small RNA would survive
long enough in the extracellular or intracellular environment to be
incorporated into a functional RISC in a recipient cell. Instead,
regardless of being found or not in exosomes, plant miRNAs or
siRNAs must be protected by plant proteins such as Argonaute-
containing complexes. To achieve function in a mammalian cell, aprotective complex would have to 1) escape digestion and disso-
ciation in the gut, in circulation, and in the recipient cell; 2) be
imported into the recipient cell cytoplasm intact; and 3) either
function in coordination with evolutionarily distant machinery in
the recipient cell, or transfer its RNA component to a mammalian
RISC. It was mentioned that uncomplexed small RNAs are a mo-
lecular dead-end and have a short half-life, and that there is no
evidence inter-RISC transfer could occur, even between two
mammalian complexes.
What of the possibility that more stable dsRNA is taken up by
ingesting mammals and subsequently processed? There is no evi-
dence that foreign dsRNA is efﬁciently imported by mammalian
cells or processed and ampliﬁed in a manner similar to what occurs
in C. elegans. Furthermore, it was mentioned that plants do not
process mammalian precursor RNAs. While it might be useful to
perform additional experiments, there is no reason to assume that
mammalian machinery would successfully process plant siRNA
precursor molecules.
Ralph Scorza of USDA-ARS reported on an RNAi-based plum he
developed, known as “Honeysweet,” which is resistant to the plum
pox virus (PPV). Interestingly, the same RNAs that confer resistance
in this plant are found at much higher levels in the virus-infected
“organic” fruits than in their transgenic counterparts. In the case
of virus resistance, then, RNAi technology can actually reduce the
exposure of the consumer to speciﬁc RNA molecules.
Chen-Yu Zhang, the corresponding author of controversial re-
ports claiming dsRNA uptake by mammals (Zhang et al., 2012a),
presented plant-based RNAs not as a threat, but rather as an op-
portunity for novel therapies of human disease. However, the
chance of either harm or beneﬁt was largely dismissed in another
presentation that reviewed the stoichiometry of dietary RNA
exposure, concluding like the FIFRA-SAP human health re-
spondents that physiologic intake and uptake of dietary RNA is
inconsistent with what is known about RNAi in mammalian cells.5.3. Comparison: FIFRA-SAP and EFSA workshop
At the Toxicology Forum, it was mentioned that the USEPA SAP,
while including sharply different and sometime contradictory
viewpoints, seemed to place relative emphasis on scientiﬁc evi-
dence, while the EFSA Workshop was set up to feature both sci-
entiﬁc and more activism-driven positions. The conclusions of the
EFSA Workshop were correspondingly equivocal, but did discard
some postulated hazards of RNAi technology, such as the possibility
that ingested RNA would saturate the mammalian RNA regulatory
machinery (Table 4). Both the EPA and EFSA meetings raised the
interest and mostly unexplored question of how the microbiome
might interact with ingested RNA.6. US FDA regulatory perspectives (Choudhuri)
The regulatory agencies and their respective regulatory
Table 4
Comparison of general consensus reached by USEPA SAP and EFSA panel.
Issue EPA EFSA
Biologically signiﬁcant uptake from
mammalian gut
No Unknown
Functional Consequences and potential
area for further study
Unlikely, but PiP-speciﬁc studies may be needed to
increase level of certainty
Consensus on the potential for off-target effects not reached
Absorption in compromised/diseased gut may
be possible.
Saturation of endogenous RNAi machinery is unlikely
Uncertainty regarding absorption after spray
applications
when compared to PIPs
Immune stimulation may be possible
Uncertainty regarding the need for dermal or
inhalation
tests
Potential effects of inhaled dsRNA by workers or the public are
uncertain
Effects on Microbiome Unknown Unknown
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Centers involved in the safety evaluation of these GE (Genetically
Engineered)2 plant varieties developed using RNAi technologies
and foods derived from them are discussed in the context of GE
crop safety assessment within the companion manuscript on pro-
tein safety in GE crops (Sherman et al., 2015). The consultation
process for GE plant varieties developed using RNAi technology is
similar in scope to that employed for transgenic proteins. FDA's
1992 “Statement of Policy: Foods Derived fromNew Plant Varieties”
(Federal Register Vol. 57 No. 104 Friday, May 29, 1992 p 22984; the
1992 policy statement) provides the framework for the safety
evaluation. In other words, the 1992 policy statement provides the
framework of safety evaluation of the GE plant varieties expressing
proteins, as well as those in which the expression of a particular
protein has been decreased (“knocked down”) by RNAi mechanism.
One unique element to the safety assessment for RNAi is that no
new protein is intended to be expressed from the RNAi sequence
element of the inserted DNA, which is different from the earlier GE
plant varieties in which the desired effect is typically gained from
the expression of an introduced protein. Plants naturally express a
plethora of small, noncoding, regulatory RNAs, which can be
consumed by humans and animals if food crops expressing them
are consumed.
The presentation concluded with examples of several GE crops
developed using RNAi technology (e.g., reduced lignin (in forage)
alfalfa; increased oleic acid soybean) for which FDA completed
consultations. In the reduced lignin alfalfa, the expression of
endogenous CCOMT gene is reduced via RNA interference resulting
in a reduced level of CCOMT enzyme, which is involved in G lignin
biosynthesis pathway. A reduced level of CCOMT enzyme results in
decreased levels of G lignin and total lignin in forage. In the
increased oleic acid soybean, the expression of FATB1-A and FAD2-
1A genes is reduced via RNA interference. Because the products of
these genes are involved in fatty acid biosynthesis pathway, the
result of RNA interference is an altered fatty acid proﬁle in soybean
that includes marked increase in oleic acid level, and an associated
decrease in linoleic acid level.
7. Discussion3
Meeting participants were supportive of the use of RNAi to
develop improved crop traits, with several commenting that they
were concerned that unless sufﬁcient outreach efforts from2 US FDA nomenclature for biotechnology-derived crops is Genetically Engi-
neered (GE). Thus, through this section GE is used instead of GM.
3 This paper is intended to describe the questions and views expressed at the
meeting, but those views may not necessarily be those of all the authors and/or
their employers.industry, academics, and government are implemented, public
perception of the technology could be inappropriately shaped by
anti-biotech non-governmental organizations (NGOs) and hinder
the acceptance of RNAi use in agricultural biotechnology.
Clariﬁcation was sought regarding how sequence matches to
humans are being characterized in regulatory submittals, if
structureeactivity relationships are considered when developing
products, and if building a library of potential mRNA targets would
be helpful. In answering these questions, it was pointed out that
there are public and private bioinformatics databases that are
available and are being updated as new sequences are discovered.
Bioinformatics is being used as a development tool to aid in
product design, with an emphasis on limiting the potential for
impacts to non-target organisms. However, the need for, and
utility of, a bioinformatics assessment to inform the risk assess-
ment of potential new RNAi plant traits in higher organisms (e.g.,
vertebrates) appears to be low due to the low concentrations in
plants, the low mammalian bioavailability of ingested dsRNA, and
the lack of correlation between sequence homology and safety in
humans and other vertebrates. Review of the calculations pre-
sented by Dr. Chan provided a reasonable estimate of the low-
dose threshold for ingested dsRNA to elicit a biological response
in humans and the wide margin of safety calculated using the
upper-bound expression levels of naturally occurring and trans-
genically expressed plant dsRNA.
Another question was raised regarding the use of bioinfor-
matics to predict potential siRNA off-target effects via analyzing
for matches between siRNAs and speciﬁc regions of target se-
quences (i.e. seed region matches), noting that some groups have
demonstrated that by taking into consideration the thermody-
namic properties of seed-target RNA duplexes, siRNAs can be
designed to greatly minimize or eliminate potential off-target
effects. The reply was that whereas the use of bioinformatics
can be used to screen for off-target matches, the potency of siRNAs
in eliciting in vivo effects is orders of magnitude lower than on
target matches with mRNA. Furthermore, off-target seed region
matches identiﬁed with bioinformatics are of questionable rele-
vance to ingested RNAs, because gene expression changes induced
by dsRNA with seed region homologies to mammalian genes are
primarily observed in cases of in vitro transfection into cultured
cells or direct injection of formulated/stabilized oligonucleotide
drugs and are, therefore, not relevant to mammals ingesting plant
expressed dsRNAs. This is because these model systems do not
consider the multiple and redundant barriers to exogenous dsRNA
exposures from the diet.
A participant asked how dsRNA for pesticide formulations
would be commercially manufactured, speciﬁcally if it would be
produced in bacteria. Currently, there are no commercial dsRNA
spray products and their commercial introduction will require
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dustrial scale dsRNA production/manufacturing processes are be-
ing investigated.
A question regarding how gut bacteria might be affected by
dsRNA was raised. It is highly unlikely that the microbiome is
impacted by dsRNAs, as humans have been consuming dsRNAs
from plants and animals throughout history without any identiﬁed
effects on the microbiome. Bacteria do not have an RNAi system,
but do posses an analogous host defense system known as CRISR/
Cas that is both phylogenetically and mechanistically different than
eukaryotic RNAi and utilizes DNA, rather than RNA as an initiating
signal (Horvath and Barrangou, 2010). Thus, dsRNAs have a very
low probability to impact the microbiome due in part to mecha-
nistic differences between RNAi and CRISPR/Cas found in
prokaryotes.
The issue of inhalation exposures was brought up during dis-
cussions in relation to inhalation of plant particles containing
dsRNA. In addition to there being a history of safe inhalation
exposure of dsRNA contained in plant pollen and dust, in general
the particle size of plant dust and pollen is larger than inhalable
particles (generally considered to be < 10 mM). As such, inhaled
pollen and plant dust particles are cleared from the upper airways
and result in secondary oral exposures, not inhalation exposures.
In general, the relative stability of dsRNA, when compared to
single-stranded RNA (ssRNA), was a novel concept for meeting
participants. Certain RNases are speciﬁc for certain types of RNA
and others act more broadly. While dsRNA tends to be more stable
than ssRNA, it can be degraded by RNases, such as those found in
blood and pancreatic secretions.
Technical questions related to the design of the oral vATPase
study (since published as Petrick et al., 2015) were raised. One
participant asked why there was not an i.v. positive control. Since
the i.v. route of exposure is not an appropriate route of exposure for
evaluating potential risks from ingesting dsRNA in plants, it is
standard practice to only use oral dosing in food safety studies. The
robust nature of the evaluated toxicology endpoints ensures that
potential toxicity of the test substances was evaluated. Also, data
developed by pharmaceutical companies indicates there is little
potential for gene suppression from i.v. dosing of dsRNA, since it is
rapidly cleared from the body after i.v. dosing. As such, there is no
known positive control. Another participant questioned why the
dose was so high (i.e., top doses of 48 mg/kg dsRNA for 28-days)
in the vATPase studies. The doses were chosen to provide very large
margins of exposure.
A question regarding the appropriateness of current chemical
and/or biotech guidance for assessing potential hazards and risk
from transgenically expressed dsRNA in plants was raised. It was
felt that current toxicology testing guidelines and existing regula-
tory frameworks are robust, appropriate for evaluation of RNAi-
based crop traits, and allow for a case-by-case approach to study
design and product evaluation. However, if a new regulatory
framework for RNAi is developed, it would be scientiﬁcally appro-
priate to determine the regulatory data needs by starting with
problem formulation, rather than creating a study checklist as is
currently done for conventional pesticides.
In summary, the session increased awareness regarding the
current and potential future beneﬁts of RNAi in agricultural
biotechnology, the state-of-the-science regarding our understand-
ing of RNAi, and the regulatory framework for evaluating the safety
of GE plants. As with any emerging technology, the potential range
of future products, potential future regulatory frameworks, and
public acceptance of RNAi technology will continue to evolve. As
such, continuing dialogue, such as promoted by The Toxicology
Forum, was encouraged to promote educated consumers and
science-based regulations.Acknowledgments
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